Wall Street analysts forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post $1.06 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The lowest sales estimate is $1.04 billion and the highest is $1.13 billion. Alexion Pharmaceuticals reported sales of $909.70 million during the same quarter last year, which indicates a positive year over year growth rate of 16.5%. The company is expected to announce its next quarterly earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $4.07 billion for the current fiscal year, with estimates ranging from $4.04 billion to $4.13 billion. For the next year, analysts forecast that the firm will post sales of $4.76 billion, with estimates ranging from $4.50 billion to $4.92 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the company posted $1.44 earnings per share. The company’s revenue for the quarter was up 19.5% compared to the same quarter last year.
A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Barclays lifted their price objective on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Evercore ISI restated an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research note on Thursday, July 26th. JPMorgan Chase & Co. lifted their price objective on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research note on Friday, July 27th. Finally, Jefferies Financial Group restated a “hold” rating and set a $123.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $161.29.
Institutional investors have recently modified their holdings of the business. Bain Capital Public Equity Management LLC raised its position in Alexion Pharmaceuticals by 23.2% in the second quarter. Bain Capital Public Equity Management LLC now owns 70,753 shares of the biopharmaceutical company’s stock worth $8,784,000 after acquiring an additional 13,318 shares in the last quarter. Brown Advisory Inc. raised its position in Alexion Pharmaceuticals by 297.9% in the second quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock worth $2,516,000 after acquiring an additional 15,169 shares in the last quarter. Essex Financial Services Inc. bought a new stake in Alexion Pharmaceuticals in the second quarter worth about $232,000. Tyers Asset Management LLC raised its position in Alexion Pharmaceuticals by 15.5% in the second quarter. Tyers Asset Management LLC now owns 6,050 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 814 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in Alexion Pharmaceuticals by 146.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,237 shares of the biopharmaceutical company’s stock worth $5,037,000 after acquiring an additional 21,555 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Shares of ALXN opened at $123.44 on Friday. Alexion Pharmaceuticals has a 1 year low of $102.10 and a 1 year high of $140.77. The firm has a market cap of $27.49 billion, a PE ratio of 23.92, a PEG ratio of 1.06 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
See Also: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.